Article

Iluvien receives positive approval from 10 more countries

Alimera Sciences' sustained-release intravitreal implant (Iluvien)-its treatment of chronic macular edema-has received a positive outcome of the Repeat-Use Procedure with the Medicines and Healthcare products Regulatory Agency of the United Kingdom serving as the Reference Member State.

 

Atlanta-Alimera Sciences' sustained-release intravitreal implant (Iluvien)-its treatment of chronic macular edema-has received a positive outcome of the Repeat-Use Procedure with the Medicines and Healthcare products Regulatory Agency of the United Kingdom serving as the Reference Member State.

The regulatory process for these 10 additional countries-consisting of Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland, and the Czech Republic-will now enter the national phase in which each country grants marketing authorization.

“Achieving a favorable outcome for (the treatment) in these additional European Union countries is a significant milestone for Alimera and very encouraging for the many patients throughout Europe with this devastating disease,” said Dan Myers, president and chief executive officer of Alimera. “We will continue to work closely with these countries during the national phase to obtain (the treatment’s) marketing authorization in each one.”

Additionally, the Italian Medicines Agency has already granted marketing authorization for the treatment.

 

Designated a C Class product in Italy, the treatment will be available initially to private-paying patients. Alimera is pursuing H Class designation for the treatment with the Italian regulatory authorities, which, if granted, would expand patient access to the product.

The Italian authorization is the seventh national approval in the European Union, preceded by Austria, the United Kingdom, Portugal, France, Germany, and Spain.

The treatment is commercially available in the United Kingdom and Germany.

 

Read more: Positive results for Aerie glaucoma therapy study

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.